The Chemical Data

VectorY and Shape Therapeutics Partner to Develop

VectorY and Shape Therapeutics Partner to Develop AAV5-Based Antibody Therapies for Neurodegenerative Diseases

VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, and Shape Therapeutics Inc. (“ShapeTX”), a leader in applying AI and RNA technologies to engineer next-generation genetic medicines, announced today that they have entered into an option and…

Read MoreVectorY and Shape Therapeutics Partner to Develop AAV5-Based Antibody Therapies for Neurodegenerative Diseases
Immuto Secures $8M Seed 2 Funding, Partners

Immuto Secures $8M Seed 2 Funding, Partners with Daiichi Sankyo on Structural Surfaceomics

Immuto Scientific today announced the closing of an oversubscribed $8 million Seed 2 financing round alongside a new drug discovery collaboration with Daiichi Sankyo, a leading global pharmaceutical company. The funding and collaboration represent significant milestones for Immuto as it…

Read MoreImmuto Secures $8M Seed 2 Funding, Partners with Daiichi Sankyo on Structural Surfaceomics
NucleoBio and PreCheck Health Partner

NucleoBio and PreCheck Health Partner on Non-Invasive Prostate Cancer Test

NucleoBio, Corp., a biotechnology innovator in precision oncology diagnostics, has announced a new strategic collaboration with PreCheck Health Services, a high-complexity CLIA-certified and CAP-accredited clinical laboratory. The partnership will support the clinical development and processing of Prostac™, NucleoBio’s proprietary diagnostic…

Read MoreNucleoBio and PreCheck Health Partner on Non-Invasive Prostate Cancer Test
Geneos’ Personalized Immunotherapy Achieves 5-Year Recurrence-Free Survival

Geneos’ Personalized Immunotherapy Achieves 5-Year Recurrence-Free Survival in Aggressive Brain and Liver Cancers

Geneos Therapeutics, a clinical-stage biotherapeutics company pioneering personalized immunotherapies for cancer (PICs), has announced remarkable clinical results from two long-term patients treated with its novel DNA-based therapy. One patient with glioblastoma multiforme (GBM), an aggressive brain cancer, and another with…

Read MoreGeneos’ Personalized Immunotherapy Achieves 5-Year Recurrence-Free Survival in Aggressive Brain and Liver Cancers
TEAM Technologies Acquires TAG3

TEAM Technologies Acquires TAG3 Engineering to Expand Medical Device Capabilities

Arlington Capital Partners a Washington, D.C.–based private investment firm with a focus on government-regulated industries, announced today that its portfolio company TEAM Technologies (“TEAM Tech”) has acquired TAG3 Engineering, LLC (“TAG3”). TEAM Tech is a leading provider of end-to-end outsourced…

Read MoreTEAM Technologies Acquires TAG3 Engineering to Expand Medical Device Capabilities
Ollin Biosciences Launches to Advance Ophthalmology Therapies

Ollin Biosciences Launches to Advance Ophthalmology Therapies

Ollin Biosciences Launches with $100 Million Financing to Advance Next-Generation Ophthalmology Therapies Ollin Biosciences, Inc., a newly established clinical-stage biopharmaceutical company, announced its launch with an initial $100 million financing round led by ARCH Venture Partners, Mubadala Capital, and Monograph…

Read MoreOllin Biosciences Launches to Advance Ophthalmology Therapies
Prota’s PRT120 Study Wins EAACI Prize

Prota’s PRT120 Study Wins EAACI Prize for Long-Term Peanut Allergy Remission

Prota Therapeutics Pty Ltd., a clinical-stage biotechnology company developing novel oral immunotherapy (OIT) treatments for food allergies, today announced that clinical research conducted in partnership with the Murdoch Children’s Research Institute (MCRI) was awarded a prestigious prize at the 2025…

Read MoreProta’s PRT120 Study Wins EAACI Prize for Long-Term Peanut Allergy Remission
Apollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis

Apollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis

Apollo Therapeutics Reports Positive Phase 2a Results for Camoteskimab in Atopic Dermatitis Apollo Therapeutics, a leading portfolio biopharmaceutical company, announced today positive topline results from its Phase 2a CHAMELEON trial evaluating camoteskimab, an investigational anti-IL-18 monoclonal antibody, in patients with…

Read MoreApollo’s Camoteskimab Meets Phase 2a Endpoint in Atopic Dermatitis